Novartis/MPM Option Fund Taps Fourth Prospect In Peptimmune
This article was originally published in The Pink Sheet Daily
Executive Summary
At Phase Ib stage, “Copaxone on steroids” for multiple sclerosis is several years from Novartis’ post-Phase II decision point.